A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

• Status: Recruiting
• Trial end date: 2025-04-01

Summary

This is a single-center single-arm phase 2 study in which patients will receive daratumumab in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity, whichever comes first. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone (ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.

• Phase: Phase 2

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Collaborator: Janssen Scientific Affairs, LLC
• Treatments: Antibodies, Monoclonal; BB 1101; Clarithromycin; Daratumumab; Dexamethasone; Dexamethasone acetate; Pomalidomide; Thalidomide